Billiontoone (NASDAQ:BLLN) Stock Price Up 11% – Should You Buy?

Billiontoone, Inc. (NASDAQ:BLLN) shares rose 11% during trading on Friday . The stock traded as high as $118.00 and last traded at $115.42. Approximately 54,080 shares were traded during mid-day trading, a decline of 72% from the average daily volume of 196,165 shares. The stock had previously closed at $104.02.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on BLLN shares. Piper Sandler assumed coverage on Billiontoone in a research report on Monday. They set an “overweight” rating and a $150.00 price target for the company. William Blair assumed coverage on shares of Billiontoone in a research report on Monday. They issued an “outperform” rating for the company. Stifel Nicolaus assumed coverage on shares of Billiontoone in a research note on Monday. They set a “buy” rating and a $145.00 target price on the stock. Wall Street Zen upgraded shares of Billiontoone to a “hold” rating in a report on Saturday, November 15th. Finally, Jefferies Financial Group initiated coverage on Billiontoone in a report on Monday. They set a “hold” rating and a $117.00 target price on the stock. Five research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $138.67.

Billiontoone Trading Up 5.2%

About Billiontoone

BillionToOne is transforming healthcare by redefining molecular diagnostics. Our revolutionary single molecule NGS (smNGS) platform achieves what was once thought impossible – detecting and precisely quantifying genetic targets with single-molecule sensitivity. At the heart of this technological breakthrough lies our patented QCTs, enabling measurements at the physical limit of detection – the single DNA molecule.